rencontres 123 Exemestane (Aromasin) significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.

http://salpasafarit.fi/?kalimo=forex-nas%C4%B1l-bir-i%C5%9F&f80=92